Mycosis fungoides is the most common type of cutaneous T-cell lymphoma. The indication affects the skin and is often localized; however, it could become metastatic and spread to other parts of the body. Mycosis fungoides most commonly affects men over the age of 50 years than in women, with a ratio of 2:1.
Currently there are limited number of approved drugs for the treatment of this indication. This has created a huge unmet need in the market for effective therapeutics that can provide either long-term relief or cure from this indication. As a result, various pharmaceutical and biotechnology companies are conducting research on developing therapeutics to capture this unmet need.
Request for: Free Sample Report
For instance, Merck is currently conducting Phase II clinical trial studies on the use of KEYTRUDA, a novel PD-1 inhibitor, for the treatment of various cutaneous T-cell lymphoma indications, including mycosis fungoides. The pipeline also witnesses the presence of various biologics being developed in Phase II and Phase III of clinical trials for the treatment of the indication. Hence, the strong R&D of pipeline molecules is expected to augment the growth of the global mycosis fungoides therapeutics market at a CAGR of 6.31% during the forecast period.